Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + hydroxychloroquine
- Development stage
- Discontinued
- Lead developer
- University of Medicine and Dentistry of New Jersey
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
docetaxel + hydroxychloroquine is a combination therapy investigated for the treatment of metastatic hormone-refractory prostate cancer. Docetaxel is a taxane-based antineoplastic agent that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to a marked decrease in free tubulin and the inhibition of mitotic cell division. Hydroxychloroquine is a 4-aminoquinoline derivative that acts as an autophagy inhibitor by increasing lysosomal pH and preventing the fusion of autophagosomes with lysosomes. The rationale for the combination is that inhibiting autophagy may overcome resistance mechanisms in prostate cancer cells, thereby enhancing the cytotoxic effects of docetaxel. This specific regimen was evaluated in a Phase II clinical trial sponsored by the University of Medicine and Dentistry of New Jersey.
- Brand names
- TaxoterePlaquenil
- Other names
- Hydroxychloroquine sulfateDocetaxel anhydrous
02
Targets
TUBB (Tubulin (alpha and beta subunits))PPT1 (Palmitoyl-protein thioesterase 1)
Beyond the preview
Go deeper on docetaxel + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + hydroxychloroquine.